Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) kindly took the time to discuss the 3-yr interim health-related quality of life (HRQoL) data from the phase 2b BE AGILE study (NCT02963506) and its open-label extension (NCT03355573) investigating bimekizumab in ankylosing spondylitis.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study’ (ABSTRACT NUMBER: 0922) was presented at the ACR Convergence, 5-9 November 2021.
- Could you tell us a little about bimekizumab and its mechanism of action? (0:14)
- What have previous phase 2 studies with bimekizumab demonstrated and what were the aims of the current analysis? (0:48)
- Could you tell us about the design of the current analysis and the overall findings? (1:33)
Disclosures: Prof. Atul Deodhar has been a consultant/ advisory board member for AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Glaxo Smith & Kline, Janssen, Moonlake, Novartis, Pfizer and UCB, and received research grants from AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatic Diseases
Juvenile Idiopathic Arthritis Awareness Week 2023 – Clare Jacklin, NRAS
Juvenile idiopathic arthritis awareness week (JIAAW) is taking place between 3-7 July to raise awareness and dispel misconceptions around JIA, this year’s theme is #BustingJIAMyths, you can take part by entering the ‘JIA Mythbuster’ quiz and joining the conversation on social media using #BustingJIAMyths and #JIAAW2023. touchIMMUNOLOGY were delighted to talk with CEO Clare Jacklin and support […]
Molecular phenotyping of giant cell arteritis patients based on the serum protein signature: Lisa Christ, EULAR 2023
There is a lack of biomarkers to profile phenotypes in giant cell arteritis (GCA) and predict potential complications. Serum protein profiling may identify molecular-based phenotypes and facilitate personalized medicine approaches. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about her study which investigated the serum protein signature of clinically defined GCA […]
Molecular Phenotyping of Giant Cell Arteritis: Lisa Christ, EULAR 2023
Giant cell arteritis (GCA) is a primary systemic vasculitis characterised by systemic inflammation and vascular insufficiency of large and medium blood vessels which may lead to end-organ damage in patients age 50 and older. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about the unmet needs in the pathogenesis of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!